Business Description
Cocrystal Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US19188J4094
Total Employee Number:
10Description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.29 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.35 | |||||
Debt-to-EBITDA | -0.16 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -65.61 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 29.4 | |||||
3-Year EPS without NRI Growth Rate | 29.4 | |||||
3-Year FCF Growth Rate | 34.9 | |||||
3-Year Book Growth Rate | -54.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 63.43 | |||||
9-Day RSI | 55.53 | |||||
14-Day RSI | 49.54 | |||||
3-1 Month Momentum % | 10.06 | |||||
6-1 Month Momentum % | 15.53 | |||||
12-1 Month Momentum % | -25.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.66 | |||||
Quick Ratio | 2.66 | |||||
Cash Ratio | 2.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.2 | |||||
Shareholder Yield % | 1.76 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -4015.11 | |||||
Net Margin % | -3924 | |||||
EBITDA Margin % | -3853.78 | |||||
FCF Margin % | -3351.28 | |||||
OCF Margin % | -3351.28 | |||||
ROE % | -143.55 | |||||
ROA % | -94.43 | |||||
ROIC % | -425.41 | |||||
3-Year ROIIC % | -1068.93 | |||||
ROC (Joel Greenblatt) % | -575.56 | |||||
ROCE % | -121.99 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 65.94 | |||||
PB Ratio | 3.53 | |||||
Price-to-Tangible-Book | 3.56 | |||||
EV-to-EBIT | -1.25 | |||||
EV-to-EBITDA | -1.3 | |||||
EV-to-Revenue | 50.16 | |||||
EV-to-Forward-Revenue | 0.57 | |||||
EV-to-FCF | -1.49 | |||||
| Price-to-Net-Current-Asset-Value | 5.56 | |||||
| Price-to-Net-Cash | 11.13 | |||||
Earnings Yield (Greenblatt) % | -80 | |||||
FCF Yield % | -52.2 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cocrystal Pharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.195 | ||
| EPS (TTM) (€) | -0.627 | ||
| Beta | 0.4705 | ||
| 3-Year Sharpe Ratio | -0.12 | ||
| 3-Year Sortino Ratio | -0.19 | ||
| Volatility % | 56.12 | ||
| 14-Day RSI | 49.54 | ||
| 14-Day ATR (€) | 0.021754 | ||
| 20-Day SMA (€) | 0.852 | ||
| 12-1 Month Momentum % | -25.6 | ||
| 52-Week Range (€) | 0.705 - 2.8 | ||
| Shares Outstanding (Mil) | 13.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cocrystal Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cocrystal Pharma Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 134 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 43 days | ||
| General meeting for 2026 | 2026-07-14 11:00 | In 13 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.06 (+0.00%) | ||
| Annual report for 2025 | 2026-03-31 | 0.87 (+0.00%) | ||
| NobleCon 21 – Noble Capital Markets 21st Emerging Growth Equity Conference | 2025-12-03 10:00 | 0.86 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 0.92 (+0.00%) | ||
| Noble Capital Markets Emerging Growth Virtual Equity Conference | 2025-10-09 12:00 | 1.03 (+0.00%) | ||
| H.C. Wainwright 27(th) Annual Global Investment Conference | 2025-09-09 12:00 | 1.25 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 1.40 (+0.00%) |
Show
Entries
Cocrystal Pharma Inc Frequently Asked Questions
What is Cocrystal Pharma Inc(FRA:8CC)'s stock price today?
The current price of FRA:8CC is €0.89. The 52 week high of FRA:8CC is €2.80 and 52 week low is €0.71.
When is next earnings date of Cocrystal Pharma Inc(FRA:8CC)?
The next earnings date of Cocrystal Pharma Inc(FRA:8CC) is 2026-08-14 Est..
Does Cocrystal Pharma Inc(FRA:8CC) pay dividends? If so, how much?
Cocrystal Pharma Inc(FRA:8CC) does not pay dividend.
Press Release
Articles on Cocrystal Pharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers